Search research articles
Contact Us
Filters
Showing results (51-60 of 134) with videos related to
Page
of 14
Sort By:
The New England Journal of Medicine
|
May 18, 2022
Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants
John P Evans, Panke Qu, Cong Zeng, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 4, 2015
TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia
Veronica Balatti, Lara Rizzotto, Cecelia Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 29, 2008
A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents
Rosa Lapalombella, Xiaobin Zhao, Georgia Triantafillou, et al.
The New England Journal of Medicine
|
June 15, 2022
Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
Panke Qu, Julia Faraone, John P Evans, et al.
BMC Medical Informatics and Decision Making
|
December 31, 2015
Classification of follicular lymphoma: the effect of computer aid on pathologists grading
Mohammad Faizal Ahmad Fauzi, Michael Pennell, Berkman Sahiner, et al.
Oncotarget
|
November 14, 2014
The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease
John T Patton, Mark E Lustberg, Gerard Lozanski, et al.
Cell Reports. Medicine
|
May 6, 2023
Neutralization escape of Omicron XBB, BR.2, and BA.2.3.20 subvariants
Julia N Faraone, Panke Qu, John P Evans, et al.
Biorxiv : the Preprint Server for Biology
|
October 27, 2022
Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2
Panke Qu, John P Evans, Julia Faraone, et al.
Cell Host & Microbe
|
December 8, 2022
Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2
Panke Qu, John P Evans, Julia N Faraone, et al.
Annals of Epidemiology
|
December 18, 2021
Prevalence of current and past COVID-19 in Ohio adults
Abigail Norris Turner, David Kline, Alison Norris, et al.
Page
of 14
Search research articles
Search
Showing results (51-60 of 134) with videos related to
Sort By:
Page
of 14
The New England Journal of Medicine
|
May 18, 2022
Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants
John P Evans, Panke Qu, Cong Zeng, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 4, 2015
TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia
Veronica Balatti, Lara Rizzotto, Cecelia Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 29, 2008
A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents
Rosa Lapalombella, Xiaobin Zhao, Georgia Triantafillou, et al.
The New England Journal of Medicine
|
June 15, 2022
Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
Panke Qu, Julia Faraone, John P Evans, et al.
BMC Medical Informatics and Decision Making
|
December 31, 2015
Classification of follicular lymphoma: the effect of computer aid on pathologists grading
Mohammad Faizal Ahmad Fauzi, Michael Pennell, Berkman Sahiner, et al.
Oncotarget
|
November 14, 2014
The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease
John T Patton, Mark E Lustberg, Gerard Lozanski, et al.
Cell Reports. Medicine
|
May 6, 2023
Neutralization escape of Omicron XBB, BR.2, and BA.2.3.20 subvariants
Julia N Faraone, Panke Qu, John P Evans, et al.
Biorxiv : the Preprint Server for Biology
|
October 27, 2022
Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2
Panke Qu, John P Evans, Julia Faraone, et al.
Cell Host & Microbe
|
December 8, 2022
Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2
Panke Qu, John P Evans, Julia N Faraone, et al.
Annals of Epidemiology
|
December 18, 2021
Prevalence of current and past COVID-19 in Ohio adults
Abigail Norris Turner, David Kline, Alison Norris, et al.
Page
of 14